Title: Flapless modified Toti’s procedure with use of circumosteal Mitomycin C as an adjunctive therapy in management of failed Dacryocystorhinostomy (DCR)

Authors: Dr Nilesh Mohan MD (AIIMS), DNB, ICO (Basic Ophtha), Dr Gyan Bhaskar MS, Dr Bibhuti P Sinha MS, Dr Ankita Kumari MS

 DOI: https://dx.doi.org/10.18535/jmscr/v7i7.169

Abstract

Aim: A Prospective study of patients to assess the success rate of repeat DCR surgery by flapless modified Toti’s rhinostomy with intraoperative use of Mitomycin C and syringing with 1 ml of 0.2mg/ml Mitomycin C on first postoperative day in newly formed passage for the treatment of failed DCR.

Methods: 60 consecutive patients (35 females and 25) males qualifying the inclusion criteria for repeat DCR,  were included in our study along with a patent upper, lower and common canaliculus. Patients less than 16 years & more than 70 years with acute attack of dacryocystitis, history of nasal or orbital trauma, secondary NLD obstruction, punctal occlusion, canaliculus obstruction and any nasal pathology causing epiphora were excluded. Surgery was performed under local anaesthesia by a single surgeon. Arruga bone trephine of 10 mm was used in all cases to make an osteum. A circumosteal intra mucosal injection of 0.02% MMC at 4 points (0.1 ml at each point) was given equally at 4 points along the edges of the ostium and 1 point in the anterior remnant of the sac. Syringing with 1 ml of 0.2mg/ml MMC was performed in newly formed passage near the bone osteum on the first postoperative day sac in all cases.

Results: The mean age of the patient was 52.45 +- 15.5 ranging from 16 to 68years comprising 35 females and 25 males. Most common presentation was a mucopurulent discharge and primary acquired nasolacrimal duct obstruction was the was the most common indication of surgery. 57 out of 60 patients were symptom free and patent on syringing at the end of follow up period of one year. No wound infection, abnormal nasal bleeding or any noticeable conjunctival and corneal complications were observed during intraoperative, postoperative or during follow up period and 3 patients had failed syringing at the end of one year possibly due to circumosteal fibrous tissue.

Conclusion: Results suggests that our modified technique had safety, reliability, high success rate and can be easily done by most surgeons.

References

  1. Toti A (1904) Nuovo metodoconservatore di curaradicaledellesuporazionichroniche del saccolacrimale. Clin Mod Firenze 10:385–389.
  2. Rabina G, Golan S, Neudorfer M, Leibovitch I. External Dacryocystorhi-nostomy: Characteristics and Surgical Outcomes in Patients with and without Previous Dacryocystitis. J Ophthalmol 2013. 2013:287524
  3. Ali, Mohammad Javed et al. “Dacryocystorhinostomy ostium: parameters to evaluate and DCR ostium scoring” Clinical ophthalmology (Auckland, N.Z.) 8 2491-9. 9 Dec. 2014
  4. Shams PN, Chen PG, Wormald PJ, et al. Management of functional epiphora in patients with an anatomically patent dacryocystorhinostomy. JAMA Ophthalmol 2014; 132(9):1127
  5. Korkut AY, Teker AM, Ozsutcu M, Askiner O, Gedikli O. A comparison of endonasal with external dacryocystorhin-ostomy in revision cases. Eur Arch Otorhinolaryngol.2011; 268:377–81.
  6. Ari S, Ku¨rs¸at Cingu¨ A, Sahin A, Gu¨n R, Kinis¸ V,Cac¸a I. Outcomes of revision external dacryocystorhinostomy and nasal intubation by bicanalicular silicone tubing under endonasal endoscopic guidance. Int J Ophthalmol. 2012; 5(2):238–41.
  7. Emine Akcay. Nilay Yuksel . Umut Ozen, Revision External Dacryocystorhinostomy Results After a Failed Dacryocystorhinostomy Surgery. OphthalmolTher (2016) 5:75–805.
  8. Abraham LM1, Selva D, Casson R, Leibovitch I.05:1106–13. Mitomycin: clinical applications in ophthalmic practice. Drugs. 2006; 66(3):321-40.
  9. Cheng HC, Sung-Huel T, Ping-Lin K, et al. Low-dose intraoperative mitomycin C as chemoadjuvant for pterygium surgery. Cornea 2001; 20:24–9.
  10. El-Guindy A, Dorgham A, Ghoraba M. Endoscopic revision surgery for recurrent epiphora occurring after external dacryocystorhinostomy. Ann Otol Rhinol Laryngol. 2000;109(4):425–30.
  11. Hartikainen J, Grenman R, Puukka P, Seppa H. Prospective randomized comparison of endonasal endoscopic dacryocystorhinostomy and external dacryocystorhinostomy. Ophthalmology 1998;105:1106–1113.
  12. Onerci M, Orhan M, Ogretmenoglu O, Irkeç M. Long-term results and reasons for failure of intranasal endoscopic dacryocystorhinostomy. Acta Otolaryngol2000;120:319-22.  
  13. Iqbal A, Khan O. External dacryocystorhinostomy with and without intraoperative mitomycin-C application in adults. Ophthalmology. 2012;10(3):262-5.
  14. Liao LS , Kao SCS, Tseng JHS, Chen MS, Hou PK. Results of intraoperative mitomycin C application in dacryocystorhinostomy. Br J Ophthalmol. 2000;84:903-6.
  15. Kao SC, Liao CL, Tseng JH, Chen MS, Hou PK. Dacryocystorhinostomy with intraoperative mitomycin C. Ophthalmology 1997;104:86-91.
  16. Tsai CC, Kau HC, Kau SC, Hsu WM, Liu JH. Efficacy of probing the nasolacrimal duct with adjunctive mitomycin C for epiphora in adults. Ophthalmology. 2002;109(1):172-4.
  17. Kamal, Saurabh M.D.; Ali, Mohammad Javed M.D., F.R.C.S.; Naik, Milind N. M.D.Circumostial Injection of Mitomycin C: Implications in Dacryocystorhinostomy: Efficacy, Safety Profile, and Outcomes.Ophthalmic Plastic and Reconstructive Surgery: March/April 2014 - Volume 30 - Issue 2 - p 187–190
  18. Ali, Mohammad Javed F.R.C.S.*; Baig, Farhana M.D., D.N.B.; Lakshman, MekalaPh.D.; Naik,   Milind N. M.D.Electron Microscopic Features of Nasal Mucosa Treated with Topical and Circumostial Injection of Mitomycin C: Implications in Dacryocystorhinostomy. Ophthalmic Plastic and Reconstructive Surgery: March/April 2015 - Volume 31 - Issue 2 - p 103–107
  19. Ugurbas SH, Zilelioglu G, Sargon MF, Anadolu Y, Akiner M, Aktürk T. Histopathologic effects of mitomycin-C on endoscopic transnasal dacryocystorhin-ostomy. Ophthalmic Surg Lasers 1997;28:300-4.  

Corresponding Author

Dr Bibhuti P Sinha MS

Professor & HOD, RIO, IGIMS, Sheikhpura, Patna, India